21277-97-4

Upstream product

• 2935-91-3 N,N'-Dibenzyl-3,3'-dithiobis(propionsaeureamid) 
• 100-46-9 benzylamine 
• 109703-12-0 N-Benzyl-4-(3-nitro-phenyl)-4-oxo-butyramide 
• 109703-10-8 m-nitrobenzoylisothiazolone 
• 81470-58-8 5-benzoyl-2-benzylisothiazol-3(2H)-one 

Downstream Products

• 642088-59-3 N-benzyl-4-bromoisothiazol-3-amine 1,1-dioxide 
• 642088-24-2 N-benzylisothiazol-3-amine 1,1-dioxide 
• 127215-25-2 2-Benzylisothiazol-3(2H)-on-1,1-dioxid 
• 68449-78-5 3-(N-benzylamino)isothiazole 
• 68449-67-2 2-benzyl-3-chloro-isothiazolium; chloride 
• 54415-03-1 2-benzyl-4,4,5,5-tetrachloro-isothiazolidin-3-one 
• 73087-44-2 3-benzylthiazole-2(3H)-one 

Relevant academic research and scientific papers

Synthesis and antibacterial activity of isothiazolyl oxazolidinones and analogous 3(2H)-isothiazolones

The synthesis and antibacterial activity of several new 5-((3-oxoisothiazol-2(3H)-yl)methyl)-3-phenyloxazolidin-2-ones 8 and analogous 2-(4-substituted phenyl)-3(2H)-isothiazolones 3 and 4 substituted at 4 and/or 3-positions of the phenyl moiety with different groups of which some have shown to increase the antibacterial activity of both 3-aryl-2-oxazolidinones and 3(2H)-isothiazolones is described. The most active compounds were isothiazolyl oxazolidinones 8a,j with unsubstituted and 8b with 4-F substituted phenyl rings which showed activities higher than analogous 3(2H)-isothiazolones and comparable or superior to linezolid, vancomycin, and ciprofloxacin against some tested microorganisms. The change in position of F and/or the use of larger substituents gave compounds with reduced or no activity. Evaluation of cytotoxicity to mouse fibroblast (NIH/3T3) cells indicated that these compounds exhibit antibacterial activity at non-cytotoxic concentrations.

Rearrangement of 5-benzoyl-3(2H)-isothiazol-3-ones to 6-benzoyl 2,3-dihydro-1,3-thiazin-4(2H)-ones

5-Benzoyl-3(2H)-isothiazol-3-ones 4 were converted to the corresponding isomeric 6-benzoyl-2-substituted-2,3-dihydro-1,3-thiazin-4(2H)-ones 13 by the following reaction sequence: the preparation of aroylpropionamides (3), the conversion of (3) to aroyliso

Isothiazoles. Part 14: New 3-aminosubstituted isothiazole dioxides and their mono- and dihalogeno derivatives

3-Alkylamino- and 3-arylamino isothiazole dioxides unsubstituted at C-4 and C-5 were synthesized starting from dithiopropionic amides. Taking advantage of the direct chlorination during the cyclization process or realizing an addition-elimination process with bromine on the final 3-aminoisothiazole dioxide derivatives, the corresponding 5-chloro-, 4,5-dichloro- or the 4-bromoisothiazole dioxides could also be made available.

Method for producing 2-alkyl-4-isothiazoline-3-one

Chlorinating agent is reacted with a compound represented by formula (I) (wherein R represents C1 to C8 alkyl groups or aralkyl groups) or a compound represented by formula (II) in a solvent in which hydrogen chloride is insoluble or has low solubility, to prepare 2-alkyl-4-isothiazoline-3-ones represented by general formula (III)

2-SACCHARINYLMETHYL ARYL CARBOXYLATES USEFUL AS PROTEOLYTIC ENZYME INHIBITORS AND COMPOSITIONS AND METHOD OF USE THEREOF

A compound having the formula: STR1 wherein Ar, R 4 and R 5 are defined herein have pharmaceutical utility as proteolytic enzyme inhibitors.

2-SACCHARINYLMETHYL ARYL AND ARYLOXY ACETATES USEFUL AS PROTEOLYTIC ENZYME INHIBITORS

4-R 4--R 5-2-Saccharinylmethyl aryl and aryloxy acetates, useful in the treatment of degenerative diseases, are prepared by reacting a 4-R. sup.4--R 5-2-halomethylsaccharin with an aryl or aryloxyacetic acid in the presence of an acid-acceptor.

2-SACCHARINYLMETHYL PHOSPHATES, PHOSPHONATES AND PHOSPHINATES USEFUL AS PROTEOLYTIC ENZYME INHIBITORS AND COMPOSITIONS AND METHOD OF USE THEREOF

4-R 1-R 2-R 3-2-Saccharinylmethyl and 4,7-C-4,5, 6,7-tetrahydro-2-saccharinylmethyl phosphates, phosphonates and phosphinates of formulas I and IIA respectively herein, useful in the treatment of degenerative diseases, and compositions containing them, methods for using them to treat degenerative diseases, and processes for their preparation by reaction of the corresponding 2-halomethylsaccharins with a phosphate, phosphonate or phosphinic acid of formula III herein in the presence of an acid-acceptor.

2-SACCHARINYLMETHYL AND 4,5,6,7-TETRAHYDRO-2-SACCHARINYLMETHYL PHOSPHATES, PHOSPHONATES AND PHOSPHINATES USEFUL AS PROTEOLYTIC ENZYME INHIBITORS AND COMPOSITIONS AND METHOD OF USE THEREOF

4-R 1-R 2-R 3-2-Saccharinylmethyl, 4-R 4-4-R 5-6-R 6-4,5,6,7-tetrahydro-2-saccharinylmethyl and 4,7-C-4,5, 6,7-tetrahydro-2-saccharinylmethyl phosphates, phosphonates and phosphinates of formulas I, II and IIA respectively herein, useful in the treatment of degenerative diseases, and compositions containing them, methods for using them to treat degenerative diseases, and processes for their preparation by reaction of the corresponding 2-halomethylsaccharins with a phosphate, phosphonate or phosphinic acid of formula III herein in the presence of an acid-acceptor.

Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof

Novel 2-substituted saccharins which inhibit the enzymatic activity of proteolytic enzymes, are useful in the treatment of degenerative diseases and have the formula STR1 wherein: L is --O--, --S--, --SO-- or --SO2 --; m and n are each independently 0 or 1; R1 is halo, lower-alkanoyl, 1-oxophenalenyl, phenyl or substituted phenyl, heterocyclyl or substituted heterocyclyl or, when L is --O-- and n is 1, cycloheptatrienon-2-yl or, when L is --S-- and n is 1, cyano or lower-alkoxythiocarbonyl or, when L is --SO2 -- and n is 1, lower-alkyl or trifluoromethyl; R2 is hydrogen, lower-alkoxycarbonyl, phenyl or phenylthio; and R3 and R4 are each hydrogen or various substituents and processes for preparation and pharmaceutical compositions and method of use thereof are disclosed.

PROTEOLYTIC ENZYME INHIBITION METHOD

4-R 4-R 5-2-Saccharinylmethyl aryl carboxylates, useful in the treatment of degenerative diseases, are prepared by reacting a 4-R. sup.4-R 5-2-halomethylsaccharin with an arylcarboxylic acid in the presence of an acid-acceptor.